RecruitingNCT05479617
Personalised Prediction of Disease Course in Ulcerative Colitis Using Multimodal Machine Learning - Part of the Presager Project
Sponsor
Copenhagen University Hospital, Hvidovre
Enrollment
400 participants
Start Date
Jun 20, 2022
Study Type
OBSERVATIONAL
Conditions
Summary
In patients achieving clinical remission following a flare, artificial intelligence can reliably predict a new flare within the next 12 months utilizing clinical and objective information at day 0 and week 8. Secondary endpoints: * An artificial intelligence model's precision in predicting a new flare within 2 and 3 years * An artificial intelligence model's precision to rule out patients who will not experience a new flare within 1, 2 and 3 year
Eligibility
Min Age: 18 Years
Inclusion Criteria3
- Signed informed consent
- Diagnosis of UC for at least 1 year
- Relapse due to UC.
Exclusion Criteria1
- Well-founded doubt that the flare is due to other than the patients UC
Interventions
OTHERDeep learning model
Use of deep learning model to predict individual patients disease course
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05479617
Related Trials
FMT in Patients With Recurrent CDI and Ulcerative Colitis: Single Infusion Versus Sequential Approach
NCT060713121 location
A Study of Vedolizumab in Adults With Ulcerative Colitis or Crohn's Disease in the Community Setting
NCT0658132891 locations
Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer
NCT0381634552 locations
A Study of Vedolizumab With Tofacitinib in Adults With Ulcerative Colitis (UC)
NCT0609512849 locations
A Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab
NCT06880744270 locations